256 related articles for article (PubMed ID: 36717859)
1. Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.
Simeone I; Ceccarelli M
J Transl Med; 2023 Jan; 21(1):55. PubMed ID: 36717859
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
3. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
4. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
5. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
6. Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W; Li Y; Wang Z
Sci Rep; 2018 May; 8(1):8256. PubMed ID: 29844492
[TBL] [Abstract][Full Text] [Related]
7. The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers.
Wee Y; Liu Y; Bhyan SB; Lu J; Zhao M
Gene; 2019 May; 697():57-66. PubMed ID: 30796966
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
9. Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
Xiao B; Chen L; Ke Y; Hang J; Cao L; Zhang R; Zhang W; Liao Y; Gao Y; Chen J; Li L; Hao W; Sun Z; Li L
BMC Cancer; 2018 Apr; 18(1):405. PubMed ID: 29642861
[TBL] [Abstract][Full Text] [Related]
10. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
11. Exomes of Ductal Luminal Breast Cancer Patients from Southwest Colombia: Gene Mutational Profile and Related Expression Alterations.
Cortes-Urrea C; Bueno-Gutiérrez F; Solarte M; Guevara-Burbano M; Tobar-Tosse F; Vélez-Varela PE; Bonilla JC; Barreto G; Velasco-Medina J; Moreno PA; Rivas JL
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365829
[TBL] [Abstract][Full Text] [Related]
12. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.
Chin SF; Teschendorff AE; Marioni JC; Wang Y; Barbosa-Morais NL; Thorne NP; Costa JL; Pinder SE; van de Wiel MA; Green AR; Ellis IO; Porter PL; Tavaré S; Brenton JD; Ylstra B; Caldas C
Genome Biol; 2007; 8(10):R215. PubMed ID: 17925008
[TBL] [Abstract][Full Text] [Related]
13. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
14. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
15. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics integration analysis unveils heterogeneity in breast cancer at the individual level.
Zhao Z; Jin T; Chen B; Dong Q; Liu M; Guo J; Song X; Li Y; Chen T; Han H; Liang H; Gu Y
Cell Cycle; 2023 Oct; 22(20):2229-2244. PubMed ID: 37974462
[TBL] [Abstract][Full Text] [Related]
17. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
18. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles.
Tegally H; Kensler KH; Mungloo-Dilmohamud Z; Ghoorah AW; Rebbeck TR; Baichoo S
PLoS One; 2020; 15(11):e0242780. PubMed ID: 33232371
[TBL] [Abstract][Full Text] [Related]
19. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
20. Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis.
Cava C; Bertoli G; Colaprico A; Olsen C; Bontempi G; Castiglioni I
BMC Genomics; 2018 Jan; 19(1):25. PubMed ID: 29304754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
